Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29689517 | 1.00 | GPR84 (0.47) | GPR84TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL4203234 | 0.78 | GPR84 (0.39) | GPR84MEN1KMT2AL3MBTL1 | |
| SCHEMBL6552971 | 0.78 | KIF11 (0.55) | GPR84S1PR1KIF11 | |
| SCHEMBL2616446 | 0.77 | MEN1 (0.41) | GPR84ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL30640907 | 0.73 | TSHR (0.50) | TSHRALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL9478733 | 0.73 | TSHR (0.44) | GPR84TSHRALDH1A1MAPK1KIF11 | |
| SCHEMBL8735028 | 0.73 | HDAC8 (0.46) | TSHRALDH1A1MAPK1KIF11 | |
| SCHEMBL26980119 | 0.73 | TSHR (0.44) | TSHRALDH1A1MAPK1KIF11CES2 | |
| SCHEMBL29644309 | 0.73 | TSHR (0.44) | TSHRALDH1A1MAPK1KIF11CES2 | |
| SCHEMBL2334903 | 0.70 | S1PR1 (0.53) | GPR84TSHRALDH1A1S1PR1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784977-A | Synthesis process of 2-chloro-3-trifluoromethylpyridine | 淄博新农基作物科学有限公司 | 2023-03-14 | — | — | CN | claimed |
| EP-2520569-B1 | PROCESSES FOR PRODUCING 2-CHLORO-3-TRIFLUOROMETHYLPYRIDINE | ISHIHARA SANGYO KAISHA (JP) | 2014-03-26 | — | — | EP | claimed |
| EP-2520569-A1 | PROCESSES FOR PRODUCING 2-CHLORO-3-TRIFLUOROMETHYLPYRIDINE | Ishihara Sangyo Kaisha, Ltd. (JP) | 2012-11-07 | — | — | EP | claimed |
| US-20120259125-A1 | PROCESSES FOR PRODUCING 2-CHLORO-3-TRIFLUOROMETHYLPYRIDINE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-10-11 | — | — | US | claimed |
| US-20240293383-A1 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-09-05 | — | — | US | disclosed |
| EP-4385574-A2 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | The Regents of the University of California (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11771687-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-03 | — | — | US | disclosed |
| EP-2004181-B3 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | UNIV CALIFORNIA (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-115784977-A | Synthesis process of 2-chloro-3-trifluoromethylpyridine | 淄博新农基作物科学有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115784977-A | Synthesis process of 2-chloro-3-trifluoromethylpyridine | 淄博新农基作物科学有限公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-3835294-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | The Regents of The University of California (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210121450-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-29 | — | — | US | disclosed |
| CN-102712590-A | Production method of 2-chloro-3-trifluoromethylpyridine | ISHIHARA SANGYO KAISHA | 2012-10-03 | — | — | CN | disclosed |
| EP-2368550-A1 | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | The Regents of The University of California (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011078296-A1 | PROCESSES FOR PRODUCING 2-CHLORO-3-TRIFLUOROMETHYLPYRIDINE | 石原産業株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
| CN-101454002-B | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | UNIV CALIFORNIA | 2011-06-08 | — | — | CN | disclosed |
| US-20110003839-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-06 | — | — | US | disclosed |
| CN-101454002-A | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | UNIV CALIFORNIA (US) | 2009-06-10 | — | — | CN | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121450-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | AR, ESRRA, NR5A1 | GPR84 407/4885TSHR 1273/4885ALDH1A1 1411/4885 |
| US-20120259125-A1 | PROCESSES FOR PRODUCING 2-CHLORO-3-TRIFLUOROMETHYLPYRIDINE | CBR3, TH, CBR1 | GPR84 4199/4885TSHR 2012/4885ALDH1A1 1163/4885 |
| US-20240293383-A1 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | AR, HRAS, NR5A1 | GPR84 146/4885TSHR 1811/4885ALDH1A1 498/4885 |
| US-11771687-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | AR, HRAS, NR5A1 | GPR84 146/4885TSHR 1811/4885ALDH1A1 498/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | GPR84 928/4885TSHR 4398/4885ALDH1A1 287/4885 |
| US-20110003839-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | AR, NR5A1, SHBG | GPR84 85/4885TSHR 1791/4885ALDH1A1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.